Precigen 2025 Q1 Earnings Misses Targets as Net Loss Widens 128%

Precigen (PGEN) reported its fiscal 2025 Q1 earnings on May 14th, 2025. Precigen's total revenue for Q1 2025 was $1.32 million, reflecting a 24.7% increase from Q1 2024. Despite the revenue growth, the company's net loss widened significantly to $54.15 million, an increase of 128.1% compared to the previous year. The earnings per share (EPS) also saw a decline, with a loss of $0.18 in Q1 2025, compared to a $0.10 loss in the previous year. The guidance remains focused on sustaining operations into 2026, excluding potential revenue from the anticipated PRGN-2012 launch.

Revenue
Precigen's revenue increased by 24.7% to $1.32 million in Q1 2025, up from $1.06 million in Q1 2024.

Earnings/Net Income
Precigen's Q1 2025 EPS showed a deeper loss of $0.18 per share compared to a $0.10 loss per share in Q1 2024, indicating a challenging financial performance.

Price Action
The stock price of Precigen has dropped 5.19% during the latest trading day, has dropped 5.19% during the most recent full trading week, and has tumbled 8.57% month-to-date.

Post-Earnings Price Action Review
The strategy of purchasing PGEN stocks when revenue exceeds expectations and holding them for 30 days has shown promising returns, delivering a 25.47% increase over the period. This performance surpasses the broader market, as exemplified by the SPY ETF, which only saw a 15.87% gain in the same timeframe. Such results underscore the strategy's potential effectiveness in capturing short-term growth following revenue beats, highlighting its merit for investors focused on capitalizing on revenue-driven market movements.

CEO Commentary
"We are extremely pleased with the progress of our PRGN-2012 program and its immense potential for RRP patients. We remain laser-focused on advancing the program toward the rapidly approaching PDUFA target action date in August. If approved, PRGN-2012 has the potential to be the first and only FDA-approved therapeutic for the treatment of RRP," stated Helen Sabzevari, PhD, President and CEO of Precigen. "We completed the first quarter with continued financial discipline while appropriately investing in activities related to the potential launch of PRGN-2012." The leadership tone reflects optimism regarding the upcoming FDA review and the product's potential market impact.

Guidance
The company anticipates that cash, cash equivalents, and investments of $81 million as of March 31, 2025, will fund operations into 2026, excluding any product-related revenue from the potential commercial launch of PRGN-2012 later this year. The FDA has granted priority review for the BLA with a PDUFA target action date of August 27, 2025. As such, the company is advancing its commercial and manufacturing readiness in preparation for this potential launch.

Additional News
In March 2025, Precigen announced a strategic collaboration with EVERSANA for the commercialization of PRGN-2012, aiming to leverage their expertise in product launch and patient access solutions. Additionally, the company reported the suspension of ActoBio operations, aligning resources towards the PRGN-2012 launch. There were no C-Level changes or dividend/buyback announcements reported during this period. These actions reflect Precigen's focused approach to streamlining operations and ensuring successful market entry for its lead therapy.